Prevnar (heptavalent pneumococcal conjugate vaccine; PCV7) provides protection against invasive pneumococcal disease (IPD) caused by vaccine serotypes. Indirect protection of non-immunised individuals may be the consequence of decreased transmission of vaccine serotypes, generally carried in the nasopharynx of infants and young children. This review summarises published reports of IPD incidence (1998-2005) among non-immunised individuals in countries with universal PCV7 immunisation. Findings suggest that non-immunised individuals benefit from indirect protection following widespread vaccination, enhancing cost-benefit evaluations of vaccination programs. Continued surveillance will be important, to follow future changes associated with non-vaccine type IPD, particularly among individuals with medical co-morbidities that may put them at higher risk of disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2006.09.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
Arch Dis Child
August 2024
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Article Synopsis
- * It analyzed data from over 26,500 infants between October 2023 and January 2024, comparing outcomes between those who received nirsevimab and those who did not.
- * Results showed significant reductions in hospital and ICU admissions due to RSV bronchiolitis, with 87.6% and 90.1% lower rates, respectively, indicating nirsevimab's potential impact on public health initiatives targeting RSV.
Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort study.
Lancet Haematol
December 2023
Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands. Electronic address:
Article Synopsis
- Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can cause serious complications like intracranial bleeding, but its prevalence in pregnancies isn't fully understood, leading to no standard screening procedures.
- A study analyzed the occurrence of clinically detectable FNAIT among HPA-1a-immunised women by monitoring a group of 913 HPA-1a-negative pregnant women who underwent routine antibody screening.
- Out of these, only one case of severe FNAIT was found (1.2%), alongside three cases of mild FNAIT (3.7%), indicating that while FNAIT is rare, it still poses risks that need further investigation for better screening methods.
Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
Vaccine
February 2024
National Biobank of Thailand, National Science and Technology Development Agency, Khlong Luang, Pathum Thani 12120, Thailand.
Introduction: Due to the data scarcity in low- and middle-income countries, we aimed to examine the incidence rate of myocarditis and pericarditis within 30 days after each dose of homologous (3 × BNT162b2) and heterologous prime-boost (2 × BBIBP-CorV/BNT162b2) vaccine regimen among individuals younger than 40 years.
Methods: We conducted a historical control cohort using routinely recorded data from Thai national vaccine and insurance claims databases. Sex-specific incidence rate ratios (IRRs) for myocarditis and pericarditis were calculated for each vaccination strategy and contrasted with incidence rates among the non-immunised population in the pre-COVID-19 period.
Signatures of T cell immunity revealed using sequence similarity with TCRDivER algorithm.
Commun Biol
March 2023
DTU HealthTech, Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
Changes in the T cell receptor (TCR) repertoires have become important markers for monitoring disease or therapy progression. With the rise of immunotherapy usage in cancer, infectious and autoimmune disease, accurate assessment and comparison of the "state" of the TCR repertoire has become paramount. One important driver of change within the repertoire is T cell proliferation following immunisation.
View Article and Find Full Text PDFRed blood cell alloimmunisation in sickle cell disease patients in the Democratic Republic of the Congo.
Transfus Med
April 2023
Département de Médecine interne, Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Democratic Republic of the Congo.
Objectives: To determine the prevalence of red blood cell (RBC) alloimmunisation and alloantibody specificity in sickle cell disease (SCD) patients in Kisangani, Democratic Republic of Congo (DRC) in comparison with those followed at the Centre Hospitalier Régional (CHR) de la Citadelle of Liège (Belgium).
Background: Data regarding RBC alloimmunisation (immune response of the organism to foreign erythrocyte antigens, antigens that lack on its own RBC) in SCD patients are scarce in sub-Saharan Africa.
Methods: We conducted a multi-site-based cross-sectional study among 125 SCD patients at Kisangani and 136 at the CHR de la Citadelle of Liège.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!